Navigation Links
Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Date:9/19/2007

COLLEGEVILLE, Pa., Sept. 19 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), presented today the first Phase 3 fracture data for bazedoxifene, a selective estrogen receptor modulator, at the American Society for Bone and Mineral Research Annual Meeting. In a three-year study, data showed that bazedoxifene 20 mg and 40 mg significantly reduced the relative risk of new vertebral fractures by 42 percent and 37 percent, respectively, compared with placebo. A post-hoc subgroup analysis of women at higher fracture risk showed that bazedoxifene 20 mg significantly reduced the incidence of non-vertebral fracture by 52 percent relative to placebo.

With regard to the safety and tolerability observed in this clinical trial, a non-statistically significant increase in the incidence of venous thromboembolic events was observed in all active treatment groups compared with the placebo group. No safety concerns related to the reproductive systems, including breast, were observed in the bazedoxifene treatment groups.

Wyeth received an approvable letter relating to its pending new drug application for bazedoxifene for the prevention of postmenopausal osteoporosis from the U.S. Food and Drug Administration (FDA) on April 23, 2007. In July 2007, Wyeth submitted a separate new drug application to the FDA for bazedoxifene for the treatment of postmenopausal osteoporosis. The efficacy data for bazedoxifene presented at the meeting represents only a portion of the totality of safety and efficacy data that the Company has submitted to FDA.

Bazedoxifene Significantly Reduced the Risk of New Vertebral Fracture

In the oral presentation, "Efficacy of Bazedoxifene in Reducing New Vertebral Fr
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Wyeth Presents Phase 3 Data for Pristiq, an Investigational Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... , Sept. 19, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... collagenase-based products marketed as XIAFLEX ® in the U.S. ... BioSpecifics, President, Tom Wegman , will present a corporate ... the Biotech Industry Conference. The presentation will ... EDT at the Millennium Broadway Hotel in New ...
(Date:9/19/2014)... -- Aufgrund der enormen Nachfrage seines ... aktualisiert, der jetzt auch die Jahre 2014 - ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und den ... Für international tätige Unternehmen geht es ... sondern darum, "wann" sie die neu in Kraft ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
(Date:9/19/2014)... 19, 2014 Follow us on ... the medical imaging market, are engineered to enhance the ... the past three decades have expanded the application roles ... iodine based agents used for over half a century ... imaging agents have witnessed sea changes, revolutionizing in the ...
(Date:9/19/2014)... 19, 2014 The ... Scandinavian style of eating, is making its ... Diet Doc’s medical weight loss ... eating good food which leads to improved ... teaching patients to understand how diet can ...
(Date:9/19/2014)... 19, 2014 Recent financial data ... industry increased their sales by 7% in the last ... trucking industry can be used as a bellwether to ... whole. This data has been proven to show trends ... freight transportation. Other non-trucking data is largely influenced by ...
(Date:9/19/2014)... MD & Salt Lake City, UT (PRWEB) September 19, ... to launch the new Activz Greens Smoothie ... Products Expo East, September 18th-20th in Baltimore, MD. ... with 8 organic super foods combined in one convenient ... Natural Products Expo East, September 18th-20th in Baltimore, MD. ...
(Date:9/19/2014)... Prussia, PA (PRWEB) September 19, 2014 ... Business Process Outsourcing solutions for Health Plans in ... Medicaid markets, will sponsor a Networking Breakfast Session ... the Health Industry Advisory Practice at Pricewaterhouse Coopers, ... at the AHIP’s 2014 National Conference on Medicare ...
Breaking Medicine News(10 mins):Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 2Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 3Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 3Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 4Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 3Health News:New Activz Greens Smoothie with 8 Organic Superfoods & More Launched at Natural Products Expo East 2Health News:New Activz Greens Smoothie with 8 Organic Superfoods & More Launched at Natural Products Expo East 3Health News:TMG Health To Sponsor Pricewaterhouse Coopers Speaker at AHIP’s National Conference on Medicare 2Health News:TMG Health To Sponsor Pricewaterhouse Coopers Speaker at AHIP’s National Conference on Medicare 3
... CORONA, Calif., Feb. 19 Watson Pharmaceuticals,Inc. (NYSE: ... branded pharmaceuticals,today reported financial results for its fourth quarter ... Fourth Quarter 2008 Results , ... increased $17.9 million or 3,percent from the fourth quarter ...
... to Vote Gold Card and Reject Dissidents, Director Slate ... (Nasdaq: LCAV ) today announced that it ... it urges support for Company management and its Board ... letter follows: To My Fellow Stockholders:Your LCA-Vision executive Team ...
... Full-Year 2009 OutlookVIRGINIA BEACH, Va., Feb. 19, 2009 AMERIGROUP ... net income for the fourth quarter of 2008 increased 20.0% ... income of $31.1 million, or $0.57 per diluted share, for ... December 31, 2008, the Company,s net loss was $50.7 million, ...
... foundation, announces its series of dental related health care reports under ... ... Springs, CO (PRWEB) February 19, 2009 -- Toxic Elements Research Foundation ... related health care reports under the title of ,Elements of Disease., ...
... greenhouse gas emissions, Oregon will face some $3.3 billion ... tab of about 4 percent of annual household income ... University of Oregon,s Climate Leadership Initiative,s Program on Climate ... Economics is guided by a steering committee of 19 ...
... Sessions begin Saturday, March 14 at 10 a.m. SAN FRANCISCO, ... and Wellness Center , is excited to bring back its ... San Francisco. Starting Saturday, March 14 at 10 a.m., ... Park or in the Presidio (near the Lyon Street Stairs) ...
Cached Medicine News:Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 2Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 3Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 4Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 5Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 6Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 7Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 8Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 9Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 10Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 11Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 12Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 13Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 14Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 15Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 16Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 17Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 18Health News:LCA-Vision Reports Tangible Results from Business Strategy 2Health News:LCA-Vision Reports Tangible Results from Business Strategy 3Health News:LCA-Vision Reports Tangible Results from Business Strategy 4Health News:LCA-Vision Reports Tangible Results from Business Strategy 5Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 2Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 3Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 4Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 5Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 6Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 7Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 8Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 9Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 10Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 11Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 12Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 13Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 14Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 15
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: